Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants

Exclusion Criteria

• •Acute coronary syndrome (ACS) within 3 months.
• •Under beta-blocker treatment for the last 2 weeks.
• •Under other medicine treatment which may affect heart rate, like Non-dihydropyridine calcium channel blockers (NDHP-CCBs) or ivabradine for the last 2 weeks; Under Digoxin treatment \[more than (\>) 0.125 milligram (mg)\].
• •Uncontrolled Diabetes \[hemoglobin A1c, (HbA1c) \>7.5%\].
• •Severe or uncontrolled hypertension \[resting Systolic Blood Pressure (SBP) \>180 millimeters of mercury (mmHg), or resting Diastolic Blood Pressure (DBP) \>110mmHg at screening period\].
• •Severe hypotension \[resting SBP less than (\<) 90mmHg, or resting DBP\<50mmHg\].
• •Resting heart rate \<60 beat per minute (bpm).
• •Any contradiction to Bisoprolol according to label, including:
• •Acute heart failure or during episodes of heart failure decompensation requiring intravenous inotropic therapy.
• •Cardiogenic shock.
• •Atrioventricular block of second or third degree (without a pacemaker).
• •Sick sinus syndrome.
• •Sinoatrial block.
• •Slowed heart rate, causing symptoms (symptomatic bradycardia),
• •Decreased blood pressure, causing symptoms (symptomatic hypotension),
• •Severe bronchial asthma or severe chronic obstructive pulmonary disease.
• •Sever forms of peripheral arterial occlusive disease and Raynaud's syndrome.
• •Untreated phaeochromocytoma.
• •Metabolic acidosis.
• •Hypersensitivity to bisoprolol or to any of the excipients.
• •Severe Arrhythmia including atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter or ventricular tachycardia.
• •Significant valvular heart disease, congenital heart disease, pulmonary heart disease or perinatal heart disease.
• •Acute pulmonary edema.
• •Severe hepatic dysfunction, defined as:
• •Serum Alanine Aminotransferase (ALT) \> triple the upper limit of the normal range; and/or
• •Serum Aspartate Aminotransferase (AST) \> triple the upper limit of the normal value range and/or
• •Severe renal dysfunction, defined as:
• •Serum creatinine \> twice the upper limit of the normal range
• •Chronic Kidney Disease (glomerular filtration rate \<45 Milliliter per minute).
• •Hyperthyroidism or hypothyroidism.
• •Severe infectious disease, example (eg) Human Immunodeficiency Virus positive or active tuberculosis.
• •Severe autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.
• •Severe respiratory, digestive, hematological disease (including Anemia of Hb \< 100 gram per litre) or tumor.
• •Known to be hypersensitivity to Bisoprolol, or any of the excipient.
• •Substance or alcohol abuse.
• •Received heart transplantation or pacemaker implantation; revascularization treatment within 3 months; or plan to receive above treatment in 6 months.
• •Currently undertaking other treatment that may affect the safety and/or efficacy evaluation, e.g. beta receptors agonists, et cetera.
• •No legal ability or legal ability is limited.
• •Subjects unlikely to cooperate in the study or with inability or unwillingness to give informed consent.
• •Child-bearing period women without effective contraceptive measures, pregnancy and lactation.
• •Participation in another clinical trial within the past 90 days.
• •Other significant condition that in the Investigator's opinion would exclude the subject from the trial.